Drug Profile


Alternative Names: LY 191617; LY 277359

Latest Information Update: 01 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Anxiolytics; Benzofurans
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Anxiety disorders; Migraine; Nausea and vomiting

Most Recent Events

  • 02 Jun 1999 A study has been added to the adverse events and the Anxiety disorders therapeutic trials sections
  • 04 Oct 1996 Discontinued-II for Anxiety disorders in Japan (PO)
  • 26 Jan 1996 Phase-II clinical trials for Anxiety disorders in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top